

Earnings Presentation IQFY22

5th August 2021


Group Performance

Group at a Glance - IQFY22



Note: I QFY2 I adjusted to reflect Daintee Ltd and Akbar Pharmaceuticals (Pvt) Ltd performance.

- LKR 7.3bn in Revenue; +28.7% YoY
- LKR | .0bn PAT; +69.2%YoY
- PATMI of LKR 333m;



- Healthcare revenue; **LKR 4.0bn**; +28.7% YoY
- Agri revenue; LKR 1.4bn; +44.2% YoY
 - 3.6m kg of palm oil, +5.9% YoY
- Consumer revenue; **LKR 1.9bn**; +22.5% YoY

Daintee revenue; LKR 470m

I,271 k kg of branded tea sold; +21.3%YoY



Group Financial Highlights


LKR m	IQ FY22	Adj. IQ FY21	Growth %	Reported IQFY21
Revenue	7,348	5,710	28.7%	4,786
EBIT	1,320	987	33.7%	860
EBIT margin	18.0%	17.3%		18.0%
PAT	1,040	615	69.2%	553
PAT margin	14.2%	10.8%		
PATMI	333	381	-12.8%	321
EPS (LKR)	0.74	0.85	-12.8%	0.72

^{*}comparative figure adjusted to include businesses purchased during FY2 I



IQ Revenue Growth Trend


5 Year CAGR of 10%



Note: I QFY21 results are adjusted to reflect Daintee Ltd and APL performance



IQ Profitability



Note: IQFY21 results are adjusted to reflect Daintee Ltd and APL performance

- Net profit of 1,040m compared to 579m Adj. net profit in IQ last year due to:
 - Better performance Healthcare Sector
 - Margin increase in Agribusiness segment due to NSA improvement in palm oil subsector

Segment Performance

Healthcare



		Adj.	
LKR m	IQ FY22	IQ FY2I*	Growth %
Revenue	4,000	3,109	28.7%
EBIT	401	339	18.3%
EBIT margin	10.0%	10.9%	
PAT	270	197	37.1%
PAT margin	6.8%	6.3%	

^{*}comparative figure adjusted to include businesses purchased during FY2 I

- IQFY22 Revenue up by 28.5% YoY due to higher sales volume in key subsectors including Pharma, MDD and Retail
- Increased health and wellness consciousness of consumers
- EBIT Margin contraction is predominantly owing to LKR currency depreciation.

 Impact was minimized by price increase certain non-price-controlled SKU's and margin improvement in MDD subsector

 sunshine holdings plc



Retail





Outlets in Colombo, and I online store

- IQFY22 revenue had increased 71.2% YoY
- Improved digital platform and delivery services
- Loyalty engagement improvement
- Improve pharma availability
- Adjusting to the new normal with change in shopper buying habits



Consumer

		Adj.	
LKR m	IQ FY22	IQ FY2I*	Growth %
Revenue	1,860	1,518	22.5%
EBIT	100	156	-36.0%
EBIT margin	5.4%	10.3%	
PAT	61	135	-54.8%
PAT margin	3.3%	8.9%	

^{*}comparative figure adjusted to include businesses purchased during FY2 l

- Revenue increase 22.5% compared to adjusted IQFY21
 - Volume growth of 21.3% in the tea subsector
 - Value growth of 25.3% in the tea subsector
- Daintee Contribution to PAT in IQFY22 LKR 36m
- Challenges faced in profitability due to
 - Tea higher RM cost and increased advertising & promotional expenses
 - Confectionery Increased RM cost

Agri



LKR m	IQ FY22	IQ FY2I	Growth %
Revenue	1,404	974	44.2%
EBIT	784	497	57.8%
EBIT margin	55.8%	51.0%	
PAT	724	406	78.1%
PAT margin	51.5%	41.7%	

- Revenue increased by 44.2% YoY mainly due to increase in NSA in the palm oil subsector
- Current herd in the Dairy Farm established at 1,645 animals, of which 781 are milking
- Dairy farm reported a PAT of LKR 18.0m in IQFY22



Additional data for analysts

LKR m	2Q FY19	3Q FY19	4Q FY19	IQ FY20	2Q FY20	3Q FY20	4Q FY20	IQ FY2I	2Q FY21	3Q FY21	4Q FY2I	IQ FY22
Revenue	5,294	5,768	6,006	5,210	5,327	5,280	5,010	4,786	6,164	6,449	6.940	7,348
PAT	443	501	-139	573	660	467	133	553	733	602	650	1,040
PATMI	234	274	-144	333	398	286	96	320	389	388	431	333

Volumes	2Q FY19	3Q FY19	4Q FY19	IQ FY20		3Q FY20		IQ FY2I	2Q FY21	3Q FY2I	4Q FY21	IQ FY22
Branded Tea (kg '000)	1,085	1,222	1.147	1,043	1,175	1,242	1,134	1,042	1,351	1,490	1,433	1,271
Palm Oil (kg 'mn)	3.7	2.7	2.9	3.3	3.8	2.8	2.3	3.3	3.2	2.2	2.3	3.6

Note: the above data is based on reported financials and thus, results of Daintee Ltd and Akbar Pharmaceuticals (Pvt) Ltd [APL] are consolidated in September 2020 and February 2021 respectively

Outlook



Outlook for 2Q FY22

Healthcare

- LKR depreciation to impact margins
- Low occupancy levels in hospitals expected during 2QFY22
- Further development of the pharma manufacturing business
- Further development of online retail platforms

Consumer

- Drive distribution synergies in retail channels
- Focus on brands to scale domestic business
- Launch of new products

Agri

- Higher palm oil NSA
- Marginal growth in volume expected
- Expand the herd to reach 1000 milking cows
- Expand dairy valueadded business



Forward Looking Statements

This presentation contains forward-looking statements that are based on management's current expectations and assumptions. Forward-looking statements include predictions of future results or activities and may contain the words "expects," "believes," "should," "will," "anticipates," "projects," "estimates," "implies," "can," or words or phrases of similar meaning. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the potential results discussed in the forward-looking statements. Our predictions could be affected by a variety of factors, including: competitive dynamics and the markets for our products, including new product introductions, advertising activities, pricing actions and promotional activities of our competitors; economic conditions, including changes in inflation rates, interest rates, tax rates, or the availability of capital; product development and innovation; consumer acceptance of new products and product improvements; consumer reaction to pricing actions and changes in promotion levels; acquisitions or dispositions of businesses or assets; changes in capital structure; changes in laws and regulations, including labeling and advertising regulations; impairments in the carrying value of intangible assets, or other long-lived assets, or changes in the useful lives of other intangible assets; changes in accounting standards and the impact of significant accounting estimates; product quality and safety issues, including recalls and product liability; changes in consumer demand for our products; effectiveness of advertising, marketing and promotional programs; changes in consumer behavior, trends and preferences, including weight loss trends; consumer perception of health-related issues; consolidation in the retail environment; changes in purchasing and inventory levels of significant customers; fluctuations in the cost and availability of supply chain resources, including raw materials, packaging and energy; disruptions or inefficiencies in the supply chain; benefit plan expenses due to changes in plan asset values and discount rates used to determine plan liabilities; failure or breach of our information technology systems; foreign economic conditions, including currency rate fluctuations; and political unrest in foreign markets and economic uncertainty due to terrorism or war.

The company undertakes no obligation to publicly revise any forward-looking statements to reflect any future events or circumstances.

Thank you

For more information, Please visit our Investor Relations page



http://www.sunshineholdings.lk/investor%20relations/index.php